BioStructures recently announced they have received FDA clearance for their new Silhouette MCS Bone Graft.
“We are very pleased to receive FDA clearance for Silhouette Mineralized Collagen Scaffold,” Russell Cook, chief executive officer of BioStructures, stated in a company release. “We founded BioStructures in 2009 with the goal to develop and commercialize proprietary first-in-class products in the bioactive, polymer, collagen and cellular bone graft spaces. The Silhouette clearance represents the third step in our attainment of that goal.”
“Looking forward, we will continue to develop our pipeline of products in a continued effort to offer a unique breadth of products all under the BioStructures umbrella.”
